Setidegrasib clinical trials
Setidegrasib is named as an intervention in 5 current clinical trials in our USA, China, France, Japan, Spain, South Korea, UK, Germany, Poland, Brazil, Taiwan and Israel registers. 4 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Astellas Pharma Global Development, Inc (3). The most-studied condition is Pancreatic Cancer. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Setidegrasib works
All drug targets →- Malignant pancreatic neoplasmPhase 3
- Non-small cell lung carcinomaPhase 3
- Pancreatic adenocarcinomaPhase 3
- Pancreatic neoplasmPhase 3
- Pancreatic ductal adenocarcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068173, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Setidegrasib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Setidegrasib
- ChEMBL
- CHEMBL6068173
- DrugBank
- DB21670
- PubChem CID
- 164875418
- CAS number
- 2821793-99-9
- FDA UNII
- 3NQ4ME292X
- Wikidata
- Q140562002
- Wikipedia
- Setidegrasib
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Setidegrasib
5 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Setidegrasib in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Setidegrasib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Randomized, Open-label, Phase 3 Study of Setidegrasib (ASP3082) versus Docetaxel in Participants with KRAS G12D-mutated Locally Advanced (Unresectable) or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on or After Platinum-based Chemotherapy and Checkpoint Inhibitor Therapy (CPI)
2025-524079-22-00 · CTIS ↗ · Neoplasms
|
Phase 3 | Authorised | Astellas Pharma Global Development Inc | Italy, Poland, Spain + 3 more |
Conditions studied with Setidegrasib
8 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Astellas Pharma Global Development, Inc | 3 |
| Astellas Pharma Inc | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Setidegrasib trials
How many clinical trials are testing Setidegrasib?
5 current trials in our USA, China, France, Japan, Spain, South Korea, UK, Germany, Poland, Brazil, Taiwan and Israel registers name Setidegrasib (also registered as ASP3082) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Setidegrasib trials recruiting patients?
Yes. 4 of the 5 trials are recruiting: 3 with sites in USA, 3 with sites in China, 3 with sites in France, 3 with sites in Japan, 2 with sites in Spain, 2 with sites in South Korea, 1 with sites in UK, 1 with sites in Germany, 1 with sites in Poland, 1 with sites in Brazil, 1 with sites in Taiwan and 1 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Setidegrasib clinical trials?
Astellas Pharma Global Development, Inc (3), Astellas Pharma Inc (1) and Gustave Roussy, Cancer Campus, Grand Paris (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Setidegrasib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Setidegrasib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Setidegrasib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.